Abstract
Objectives Providing valuable information on the prevalence of Covid-19 is a crucial step to improve and accentuate the disease surveillance and prevention system as this can limit the spread of the virus.
Methods COVID-19 is caused by the SARS-CoV-2 virus. It is essential to understand the epidemiological characteristics of the first cases in each country. The purpose of this study is to describe the geographic distribution and some risk factors in the first thousands of cases in Algeria. This descriptive study was carried out to examine recent data published by public health institutions in Algeria, websites and the world health organization.
Results The 8306 cases of COVID-19 have been confirmed in Algeria. By sex, men with 55.76% predominate, the most affected age group was 25 to 49 years old (41.1%), 600 cases of death were reported, subjects aged over 60 years are the most likely to die from COVID-19. Most of the confirmed subjects came from the cities of Blida and Algiers. All cases are human-to-human transmissions.
Conclusion The COVID-19 pandemic has highlighted the lack of dical equipment in Algeria and in all countries of the world. This requires better management of the health sector on an international scale.
Competing Interest Statement
The authors have declared no competing interest.
Clinical Trial
It is an original study
Funding Statement
no funding statement
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
no details
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All data used in this study are available
